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Abstract
Background The purpose of this project was to develop a telemedicine platform that supports home site monitoring and
integrates biochemical, physiological, and dietary parameters for individual patients with hepatic glycogen storage disease
(GSD).
Methods and results The GSD communication platform (GCP) was designed with input from software developers, GSD
patients, researchers, and healthcare providers. In phase 1, prototyping and software design of the GCP has occurred. The
GCP was composed of a GSD App for patients and a GSD clinical dashboard for healthcare providers. In phase 2, the GCP
was tested by retrospective patient data entry. The following software functionalities were included (a) dietary registration and
prescription module, (b) emergency protocol module, and (c) data import functions for continuous glucose monitor devices and
activity wearables. In phase 3, the GSD App was implemented in a pilot study of eight patients with GSD Ia (n = 3), GSD IIIa
(n = 1), and GSD IX (n = 4). Usability was measured by the system usability scale (SUS). The mean SUS score was 64/100
[range: 38–93].
Conclusions This report describes the design, development, and validation process of a telemedicine platform for patients with
hepatic GSD. The GCP can facilitate home site monitoring and data exchange between patients with hepatic GSD and healthcare
providers under varying circumstances. In the future, the GCP may support cross-border healthcare, second opinion processes
and clinical trials, and could possibly also be adapted for other diseases for which a medical diet is the cornerstone.
Keywords Hepatic glycogen storage diseases . Telemedicine . Monitoring . Mobile application . Dietary management . Rare
diseases
Abbreviations
API Application programming interface
CE Conformité Européenne
CGM Continuous glucose monitoring
GCP GSD communication platform
GSD Glycogen storage disease
DM Diabetes mellitus
IoT Internet of things
MetabERN European Reference Network for Rare
Hereditary Metabolic Disorders
SUS System usability scale
TM Telemedicine
Introduction
Hepatic glycogen storage diseases (GSDs) are a group of in-
born errors of carbohydrate metabolism, for which a strict diet
is the cornerstone of management. Patients with hepatic GSD
display perturbed glucose homeostasis due to a deficiency of a
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functional enzyme or transporter in glycogen synthesis, gly-
cogenolysis, and/or gluconeogenesis. This generally leads to
fasting intolerance, failure to thrive and hepatomegaly, and is
biochemically associated with (non)ketotic hypoglycemia,
(fasting or postprandial) hyperlactacidemia, increased liver
enzymes and hyperlipidemia (Walter et al 2016). The aim of
dietary management is to maintain euglycemia, to suppress
secondary metabolic derangements and to prevent long-term
complications. The natural histories of several subtypes of
hepatic GSD were reported by international cohort studies
(Rake et al 2002a; Sentner et al 2016), review articles (Bali
et al 2006; Dagli & Weinstein 2009; Goldstein et al 2011;
Dagli et al, 2010; Magoulas & El-Hattab 2013), and guide-
lines (Rake et al 2002b; Visser et al 2002; Kishnani et al 2010;
Kishnani et al 2014).
In line with the observations that strict diabetes manage-
ment prevents long-term complications, observational cohort
studies of GSD I patients have emphasized the importance of
good metabolic control for the prevention of liver adenomas
(Wang et al 2011), nephropathy (Wolfsdorf et al 1997;
Martens et al 2009; Melis et al 2015; Okechuku et al 2017)
and bone disease (Minarich et al 2012; Melis et al 2014). For
GSD IIIa patients, an association between overtreatment with
carbohydrates and hypertrophic cardiomyopathy was sug-
gested by several case-reports (Dagli et al 2009;
Valayannopoulos et al 2011; Sentner et al 2012). In addition,
a case report on two patients with GSD IXa presented im-
provement in liver cirrhosis on ultrasound after improving
metabolic control (Tsilianidis et al 2013).
Continuous glucose monitoring (CGM) systems have been
developed to facilitate glucose monitoring. Originally, CGM
systems were developed for patients with diabetes mellitus
(DM) (Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring Study Group 2008), but the application
of CGM in GSD patients has also been reported by several
groups (Hershkovitz et al 2001; Maran et al 2004; White &
Jones 2011; Kasapkara et al 2014). The introduction of CGM
systems has increased opportunities for home site monitoring.
Nevertheless, day-to-day healthcare for the GSD patients is
still challenging ofwhich suboptimal metabolic control is only
one of many reasons (as summarized in Table 1).
Telemedicine (TM) has emerged rapidly as a novel tool to
deliver healthcare tailored to the individual patient’s needs
(Moore 1999; Steinhubl et al 2015; Heintzman 2016).
Besides this, TM seems promising to provide cross-border
healthcare for patients with rare diseases (Saliba et al 2012).
Surprisingly, to date, there is only one publication on a mobile
application for dietary management of patients with inborn
errors of metabolism (Ho et al 2016).
To support home site monitoring and to integrate
biochemical, physiological, and dietary parameters, we
have designed, validated, and implemented a TM plat-
form for patients with hepatic GSD. This TM platform,
now further referred to as GSD communication platform
(GCP), consists of the GSD application (GSD App) for
patients and their caregivers and the GSD clinical dash-
board for healthcare providers.
Methods
The GCP was intended to support rather than replace current
healthcare as provided by our center of expertise for hepatic
GSD and recommendations were only generated after approv-
al by a healthcare provider. The usability pilot study has been
carried out in accordance with ethical and legal guidelines of
the University Medical Center Groningen (Medical Ethical
Committee, 2016/466) and The Code of Ethics of the World
Medical Association (Declaration of Helsinki). Technical
documentation and user manuals of the GCP were pre-
pared for the validation of the GCP as a class I medical
device, as described in the Medical Device Directive 93/
42/EEC. The creation of the technical documentation
was supported by DRS consultancy (http://drs.nu/en_
US/) and subsequently reviewed by the quality
consultant medical devices of the University Medical
Center Groningen, in preparation of notifying the GCP
to the national Inspectorate of Health for a Conformité
Européenne (CE) mark.
For the software development and validation process of the
GCP, three phases were constructed.
Table 1 Challenges in current healthcare for individual patients with hepatic GSD
1. Suboptimal metabolic control (due to under- or overtreatment with carbohydrates) still occurs, associated with co-morbidity and long-term
complications.
2. There is a gap of knowledge between clinical guidelines and management in daily practice.
3. There is large heterogeneity between individual patients with identical GSD subtypes and genotypes
4. There is a discrepancy between prescribed diets and actual used diets.
5. Clinical parameters are mostly measured in the hospital on relatively random moments.
6. Traditional biomarkers are suboptimal and biochemically distant from the primary metabolic block.
7. Patients with rare diseases usually do not live close to so-called centers of expertise, which challenges ‘shared care models’.
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Phase I — Prototyping and software design:
The GCP was designed during monthly meetings with
input from software developers, (parents of) GSD pa-
tients, researchers, and healthcare providers from
June 2014 till present. The GCP was composed of two
web applications; the GSD App for patients and their
caregivers and the GSD clinical dashboard for healthcare
providers. The GSD App was developed in Dutch, the
native language for most of our patients, whereas the
GSD clinical dashboard was developed in English.
Figure 1 presents the detailed architecture of the GCP.
Intended uses— The intended use of the GSD App is to
allow individuals with hepatic GSD to support their die-
tary management provided by healthcare providers, un-
der normal circumstances and intercurrent illness, by
monitoring and sharing home site collected data with
healthcare providers. The intended use of the GSD clin-
ical dashboard is to integrate data collected by hepatic
GSD patients, either at home or during a hospital admis-
sion, and to provide subsequent GSD dietary manage-
ment advice for normal circumstances, intercurrent ill-
ness, and those situations where the emergency protocol
is applicable.
Data security and management— For both applications,
the Hypertext Transfer Protocol Secure (HTTPS) and the
Open Web Application Security Project Top Ten aware-
ness document (https://www.owasp.org/) was adopted to
secure integrity and privacy of online communication
within the GCP. Access to the applications required a
username and password. Passwords were stored with a
salted and one-way encryption method to protect from
accidental or unlawful loss. Software test plans and com-
plaints management procedures were set up for post-
market evaluation. The GCP was hosted on Microsoft
Azure (refer to Azure subscription agreement: https://
azure.microsoft.com/en-us/support/legal/subscription-
agreement/). For the GSD App development, the open
source frameworks AngularJS, JavaScript jQuery, and
Bootstrap were chosen. A non-commercial license from
Highcharts (https://www.highcharts.com) was used to
display the graphs in the GSD clinical dashboard.
Phase II— Software development and retrospective clin-
ical data entry:
Features and functionality were reviewed and issues on
usability were managed, processed, and documented with
the use of a Jira issue tracker from Atlassian® by software
developers, researchers, and healthcare providers.
The following software functionalities were included:
Dietary registration and prescription module — The
Dutch Food Composition Table (NEVO table) (National
Institute for Public Health and the Environment 2012)
was used for the development of the dietary registration
module in the GSD App and the prescription module for
dieticians in the GSD clinical dashboard, respective-
ly. The NEVO table contains information on macro-
and micronutrients content and total kilocalories of
all food items frequently eaten by the Dutch popu-
lation. The NEVO table also includes data on the
medical formulas, dietary supplements, maltodextrin
products, and uncooked cornstarch, such as
Glycosade®.
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Fig. 1 Architecture of the GSD
communication platform.
Legend: 1, no API was available
for the CGM data, these data were
manually imported to the GSD






Emergency protocol module— The local hospital emer-
gency protocol guideline was used as a template for the
emergency protocol module in the GSD clinical dash-
board. The emergency protocol module was designed in
such a way that it could automatically generate an emer-
gency letter with the use of the patient’s GSD type and
actual body weight. After generation, the emergency let-
ter was shared with the corresponding patient in the GSD
App.
Data import functions— In the GSD clinical dashboard,
an import function for CGM data (Dexcom G4/G5 CGM
system, Dexcom Inc., San Diego, CA) was created. An
Application Programming Interface (API) was acquired
by Fitbit, Inc. to import data from the activity wearable in
the GSD App.
Retrospective data entry — Data from written food and
clinical measurement diaries were retrospectively collect-
ed in the GCP by the researchers to test the usability and
correctness of the GCP functionalities. These data were
from patients who visited the University Medical Center
Groningen GSD center of expertise between March and
October 2016 and who gave written informed consent for
the use of their data collected during their visit.
Phase III — Implementation and pilot study prospective
clinical data entry:
Subjects and pilot study design — Between March and
July 2017, data were prospectively collected in the GCP
by selected GSD patients visiting our center. Patients
were introduced to the GSD App by the treating physi-
cian (TGJD) and researcher (IJH). All subjects received
an up-to-date manual for the use of the GSD App. Data
exchange was requested by the healthcare provider to
allow individual data integration in the GCP and critical
follow-up after dietary changes. Subjects were asked to
use the GSD App for home site monitoring before, dur-
ing, and/or after a clinic visit, according to the purpose of
their visit. Furthermore, subjects could temporarily use an
activity wearable with a heart rate function (Fitbit Charge
HR™). A CGM system by Dexcom was used only when
needed for regular care. Data from the CGM were retro-
spectively imported in the GSD clinical dashboard by the
healthcare providers. Results of data integration in the
GSD clinical dashboard (i.e., updated dietary plans and
emergency protocols) were discussed with the subjects/
patients and their parents during the outpatient clinic visit
and/or via a telephone or videoconference consultation
following the (outpatient) clinic visit.
Survey methods — User feedback was documented in a
structured logbook and usability issues from different
users (patients, caregivers, and healthcare providers) were
uploaded in the Jira issue tracker for further software
improvements. Subjects and/or caregivers were asked to
give feedback on the GSD App via an open feedback
form on paper or electronically via a SurveyMonkey
questionnaire and to fill in the system usability scale
(SUS) (Brooke 1996). An adjective scale was used for
the interpretation of individual SUS scores (Bangor et al
2009).
Results
Phase I: prototyping and software design
Figure 2 displays screenshots of the GSD App and the GSD
clinical dashboard. The GSDApp can be accessed by going to
https://app.gsdapp.nl in the internet browser on a mobile
phone. The GSD clinical dashboard can be accessed via a
desktop browser: https://clinicaldashboard.gsdapp.nl.
Phase II: software development and retrospective
clinical data entry
Access to individual patient registered data in the GSD App
was restricted to the patient user and their caretakers. Data
share requests by healthcare providers via the GSD clinical
dashboard (for instance, for the preparation of an outpatient
clinic visit) were only answered by and with the permission of
(the caretakers of) the patient.
Data import and visualization The combo graph in the GSD
clinical dashboard displayed combined data of the patient
from the requested period in one interactive graph (see Fig.
2c). The GSD clinical dashboard also displayed a histogram
and a pie chart to provide more insight into the differences in
macronutrient distributions and total calorie intake between
prescribed and registered diets.
Dietary prescription module The implementation of the
NEVO table supported dietary registration, prescription, and
macronutrient calculations. An extra function was added for
the entry of drip-feeding to simplify the determination of the
rate of drip-feeding in milliliters per hour and the macronutri-
ent intake.
Retrospective data entry Table 2 summarizes retrospective
data on dietary management and CGM profiles from five pa-
tients with GSD Ia (n = 3), GSD IIIa (n = 1), and GSD IX (n =
1). Improvements for dietary registration in the GSD App and
data visuals in the GSD clinical dashboard were implemented.
Eventually, retrospective data entry led to the development of
the GSD App and GSD clinical dashboard versions for the
usability pilot study in phase III.
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Phase III: implementation and pilot study prospective
clinical entry
Subjects The GSD App was prospectively used by eight pa-
tients with GSD type Ia (n = 3), IIIa (n = 1), and IX (n = 4).
Table 2 presents an overview of the patients’ characteristics.
Three patients participated in both the retrospective clinical
data entry and the pilot study. The GSDApp was used by both
GSD patients (n = 3) and caregivers (n = 5). Patient #P01 used
the GSD App together with her parents as a first step toward
autonomy.
Pilot study outcome Table 2 displays the different purposes
for which the GSD App was used. In phase III (P02, P04-
P08), data were collected in the GSD App outside the hospital
environment. The distance to our hospital ranged between 158
and 397 km, emphasizing the potential in home site monitor-
ing. Only one patient used the activity wearable (Fitbit Charge
HR™) to monitor heart rate and activity as an extra physio-
logical marker for the assessment of his sport regimen.
Feedback from users Feedback on the GSD App could be
collected for 7/8 GSD App users (see Table 2), unfortunately
#P02 has not returned written feedback, despite reminders.
The mean SUS score was 64/100 [range: 38–93]. Two sub-
jects scored the GSD App usability with ‘excellent’ on the
adjective scale for interpretation of individual SUS scores.
The mean SUS was higher among parents with younger chil-
dren (n = 3, mean SUS 83) compared to adult patients or par-
ents with older children (≥12 years of age) (n = 4, mean SUS
50). Patients reported in the open feedback form that it was
easy to have their dietary prescription at hand and that the
GSD App worked more efficiently compared to the paper
food diaries. Points for improvements were the search strategy
for the right food items and the feedback from healthcare
providers on registered data.
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Fig. 2 Screenshots from the
GSD App and the GSD clinical
dashboard: a) the home screen,
b) the logbook, c) evaluation
display in the GSD clinical
dashboard. Legend: a) the
cutlery button presents the
prescribed diets; the share button
displays the users and the shared
data periods. The emergency
protocol and personal emergency
phone numbers are accessible via
the information button. b) the
logbook gives a clear overview of
all registered meals over the day
in a chronological manner.
Macronutrient totals can be
displayed per food item, per meal,
and/or per day. Besides dietary
registration, the GSD App allows
patients to enter their blood
glucose/ketones measurements,
physical activities, and
symptoms. c) the combo graph in
the GSD clinical dashboard
presents all individual data in one
interactive graph. Data sets can be
added or deleted from the graph
Discussion
This report describes the design, development, and validation
process of a TM platform for patients with hepatic GSD. The
GCP can facilitate home site monitoring and data exchange
between patients with hepatic GSD and healthcare providers
under varying circumstances. Rather than a study or a project,
the development and maintenance of a TM platform for med-
ical use is a continuous process responding to individual needs
of patients and healthcare providers, technological and socie-
tal advancements, and the changing (international) legislation,
as discussed below.
The GCP has been developed as a supportive tool for GSD
patients and healthcare providers in our center of expertise.
The GSD App allows patients to easily collect data at home as
a preparation for an outpatient clinic visit, for the monitoring
of in-hospital dietary interventions, and for the evaluation of
metabolic control at home and during physical activity. In
addition, the GSD App gives patients access to their individ-
ual dietary management plan and emergency letter. Based on
the collected SUS scores in the pilot study, it can be suggested
that parents of GSD patients are in more need of a home site
monitoring tool like the GSD App to manage everyday care
for their child. The GSD clinical dashboard for healthcare
providers facilitates diet prescription and emergency letter
generation. Furthermore, the GSD clinical dashboard offers
healthcare providers the possibility to analyze home site col-
lected data from the individual patient. For several hepatic
GSD subtypes there are international guidelines (Rake et al
2002b; Visser et al 2002; Kishnani et al 2010; Kishnani et al
2014), but local and national circumstances need to be con-
sidered when the GCP would be implemented in other centers
of expertise.
The connection of measure devices with the patient can be
defined as the Internet of things (IoT) in healthcare (Dimitrov
2016). IoT allows real-time and home site collected data shar-
ing and integration, and eventually a better response to indi-
vidual data. In general, data ownership within IoT is still in the
gray area, because of the absence of transparent data regula-
tion (Dinesen et al 2016; Kostkova et al 2016). We created
different interactivities between the GCP and other technolo-
gies, such as the CGM systems and activity wearables. During
the pilot study, data visuals within the GCP were only acces-
sible for healthcare providers in the GSD clinical dashboard.
An important point of feedback from the patients and their
parents was the lack of interactivity of home site collected
data and the visibility of these data in the GSD App for the
patients themselves.













Phase II: retrospective clinical data entry
R01 12 Ia F Nocturnal Glycosade® versus CNGDF ✓ ✓ ✓ ✓
R02 31 Ia M Regular outpatient clinic visit for metabolic monitoring ✓ ✓ ✓ ✓
R03 36 IIIa F Monitoring introduction of MCT ✓ ✓ ✓ ✓
R04 0 IX M Metabolic monitoring during breastfeeding on demand – ✓ – –
R05 19 Ia M Metabolic monitoring ✓ ✓ – ✓
Phase III: pilot study prospective clinical data entry SUS score
(1–100)
P01 13 Ia F dNocturnal Glycosade® versus CNGDF ✓ ✓ – ✓ 38
P02 0 IX M dRegular outpatient clinic visit for metabolic
monitoring
✓ ✓ – ✓ no
response
P03 31 Ia F Introduction of Glycosade® as late night drink ✓ ✓ – ✓ 55
P04 1 IX M Regular outpatient clinic visit for metabolic monitoring ✓ ✓ – ✓ 93
P05 50 IX M Monitor of sport regimen ✓ – ✓ – 63
P06 4 IIIa F Regular outpatient clinic visit for metabolic monitoring ✓ – – ✓ 75
P07 20 Ia M dRegular outpatient clinic visit for metabolic
monitoring
✓ ✓ – ✓ 45
P08 5 IXc M Regular outpatient clinic visit for metabolic monitoring ✓ – – ✓ 80
CGM continuous glucose monitoring, CNGDF continuous nocturnal gastric drip feeding,MCT medium chain triglycerides, SUS system usability scale
a Age of the patient during data period entered in the GSD App
b Logbook entry included dietary registration and measurements
c Import of activity wearable data by Fitbit
d This patient was also included in the retrospective clinical data entry
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The revolution of the internet has generated increasing in-
terest for home site or remote monitoring in healthcare that
can overcome many of the issues listed in Table 1. The Dutch
Federation of Medical Specialists published the vision docu-
ment Medical Specialist 2025 that lists four essential require-
ments for future healthcare: (a) a holistic approach by the
healthcare provider for each individual, unique patient, (b)
digital developments to support network medicine, (c) focus
on health, behavior, and functional maintenance to prevent
disease, and (d) implementation of big data analysis, wear-
ables, and home diagnostics in self-management of chronic
diseases. More recently, Augustine and co-workers reported
a novel healthcare model for patients with rare diseases that
focusses on TM, integration of care and research, and improv-
ing patient–clinician–researcher collaborations (Augustine
et al 2017). In line with the so-called care continuum model,
continuous maintenance and improvement of the GCP will
occur in collaboration with the patients and their caregivers.
Currently, there is only one report on a mobile application for
dietary management of patients with inborn errors of metabo-
lism (Ho et al 2016). Our project may serve as an example to
design, validate, and implement a unique TM platform for and
together with patients with rare diseases.
Some limitations need to be addressed. First, we performed
a pilot study with a small number of patients only focusing on
the usability and functionalities of the GSD App. Future re-
search must focus on the effect of the GCP intervention on
metabolic control, quality of life, and cost-effectiveness.
Usability of the GSD clinical dashboard for healthcare pro-
viders should also be studied. Second, new versions of the
GSD App have been released in between the collection of
SUS scores. Continuous improvement of the GSD App based
on patient’s feedback was possible due to close collaboration
with the patient population and software developers, but there-
fore SUS score interpretation should be done with caution.
Third, for the development of the GCP, the team collaborated
especially with parents of GSD patients, hence the needs of
(young) patients may have been underestimated.
Currently, the European Medical Device Directive 93/42/
EEG is still the legal fundament guiding CE mark procedures
of medical software, whereas ISO 14155:2011 addresses the
good clinical practice of clinical investigations with humans to
assess the safety and performance of medical devices. Since the
start of our project, however, in our rapidly changing technolog-
ical society, newEuropean legislation has been approved regard-
ing medical devices (i.e., the Medical Device Regulation MDR
2017/745) and data privacy (i.e., the General Data Protection
Regulation). Hence, technical, societal, medical, and legal de-
velopments are continuously influencing the process, demon-
strating the complex dependency of different stakeholders to
support healthcare for our patients and their caregivers.
Future perspectives and applications of the GCP are nu-
merous. The platform could facilitate cross-border healthcare,
support second opinion processes, and provide support during
clinical trials. In theory, the GCP could be adapted for patients
with congenital hyperinsulinism and ketogenic diets (i.e., oth-
er rare conditions in which glucose homeostasis is perturbed)
and inherited metabolic diseases for which a medical diet is
the cornerstone. For these purposes, multiple translations and
integration of the GCP with national food databases and elec-
tronic patient file systems will be crucial. The — in 2016
formally recognized — European Reference Network for
Rare Hereditary Metabolic Disorders (MetabERN) could sup-
port the generation and (financial) maintenance of such TM
projects (Raposo 2016; Héon-Klin 2017), or alternatively, pa-
tient organizations.
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